Nurlan Dauletbaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nurlan Dauletbaev has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Beate Sigrid Mueller
Institute of General Practice, University of Cologne, Cologne, Germany
4 shared publications - Claus Vogelmeier
Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research (DZL), Marburg, Germany
3 shared publications - Gernot Rohde
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Marburg, Philipps-University Marburg, Marburg, Germany
3 shared publications Michael Dreher
Medizinische Klinik V, Klinik für Pneumologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen
3 shared publicationsSebastian Kuhn
Institute for Digital Medicine, University Hospital Giessen and Marburg, German Center for Lung Research (DZL), Philipps-University of Marburg
3 shared publications- Sebastian Kuhn
Institut für Digitale Medizin, Philipps-Universität Marburg & Universitätsklinikum Marburg, Marburg, Deutschland
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1927835
Common barriers and facilitators to the implementation of digital medicine in chronic respiratory diseases: a systematic review of reviews
Background and research question: Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19? Study design and methods: Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013). Results: No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators. Conclusion: High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944 , PROSPERO, CRD420251070944.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1927835
Open AccessCommon barriers and facilitators to the implementation of digital medicine in chronic respiratory diseases: a systematic review of reviews
Background and research question: Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19? Study design and methods: Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013). Results: No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators. Conclusion: High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944 , PROSPERO, CRD420251070944.
- Open Access
- 18 September 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e58364
Home Monitoring Delivered Through the Emergency Department for Outpatients With COVID-19: COVID19@Home Aachen Pilot Cohort Study
Background: The overwhelming COVID-19 situation in 2020/2021 required novel approaches that did not require additional personnel within the current health care system. Therefore, we initiated a trial of nonsupervised home monitoring via the emergency department of a tertiary hospital without the support of a virtual ward as part of the “Netzwerk Universitaetsmedizin” cooperation in Germany. Given that daily vital sign checks for inpatients with COVID-19 could indicate clinical deterioration, this approach might also be helpful in an outpatient setting and could help to identify the need for hospitalization and additional resources. Objective: This study aims to determine whether patient-led home monitoring for acute SARS-CoV-2 infection can be implemented through the emergency department of a tertiary care provider. Methods: Patients who tested positive for SARS-CoV-2 infection in our emergency department between May 2021 and May 2022, did not have a medical indication for hospitalization, and were discharged to the outpatient setting were offered the opportunity to perform nonsupervised home monitoring of vital signs. Those who agreed to participate received Bluetooth-enabled devices to measure temperature, oxygen saturation, and blood pressure and downloaded a smartphone app. Participants were encouraged to measure their vital signs for at least 28 days. There was no virtual ward or real-time surveillance of the recorded data, but these could be made available to primary care physicians. Compliance with self-measurements was determined, and participants were contacted after the monitoring period for a semistructured interview. Results: A total of 828 patients with COVID-19 were treated at the emergency department. Of these, 262 were directly discharged into ambulatory isolation after initial assessment, 25 were offered the opportunity of nonsupervised home monitoring, 15 successfully activated the devices, and 9 performed more than one complete measurement using the app. These 9 participants used the devices for an average of 15.8 days after discharge. Interviewed participants reported various difficulties with device setup but said they were pleased to use home monitoring and felt that the measurement option gave them additional security. Conclusions: This study highlighted the challenges associated with implementing nonsupervised home monitoring for outpatients with COVID-19 who presented to the emergency department of a tertiary hospital. Implementing such a system without the involvement of additional personnel does not appear to be the optimal approach. We suggest that the physician-patient relationship might be a factor that is essential for the success of patient-led approaches to home monitoring.
- 18 September 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e58364
Open AccessHome Monitoring Delivered Through the Emergency Department for Outpatients With COVID-19: COVID19@Home Aachen Pilot Cohort Study
Background: The overwhelming COVID-19 situation in 2020/2021 required novel approaches that did not require additional personnel within the current health care system. Therefore, we initiated a trial of nonsupervised home monitoring via the emergency department of a tertiary hospital without the support of a virtual ward as part of the “Netzwerk Universitaetsmedizin” cooperation in Germany. Given that daily vital sign checks for inpatients with COVID-19 could indicate clinical deterioration, this approach might also be helpful in an outpatient setting and could help to identify the need for hospitalization and additional resources. Objective: This study aims to determine whether patient-led home monitoring for acute SARS-CoV-2 infection can be implemented through the emergency department of a tertiary care provider. Methods: Patients who tested positive for SARS-CoV-2 infection in our emergency department between May 2021 and May 2022, did not have a medical indication for hospitalization, and were discharged to the outpatient setting were offered the opportunity to perform nonsupervised home monitoring of vital signs. Those who agreed to participate received Bluetooth-enabled devices to measure temperature, oxygen saturation, and blood pressure and downloaded a smartphone app. Participants were encouraged to measure their vital signs for at least 28 days. There was no virtual ward or real-time surveillance of the recorded data, but these could be made available to primary care physicians. Compliance with self-measurements was determined, and participants were contacted after the monitoring period for a semistructured interview. Results: A total of 828 patients with COVID-19 were treated at the emergency department. Of these, 262 were directly discharged into ambulatory isolation after initial assessment, 25 were offered the opportunity of nonsupervised home monitoring, 15 successfully activated the devices, and 9 performed more than one complete measurement using the app. These 9 participants used the devices for an average of 15.8 days after discharge. Interviewed participants reported various difficulties with device setup but said they were pleased to use home monitoring and felt that the measurement option gave them additional security. Conclusions: This study highlighted the challenges associated with implementing nonsupervised home monitoring for outpatients with COVID-19 who presented to the emergency department of a tertiary hospital. Implementing such a system without the involvement of additional personnel does not appear to be the optimal approach. We suggest that the physician-patient relationship might be a factor that is essential for the success of patient-led approaches to home monitoring.
- Open Access
Implementing remote monitoring for COVID-19 patients in primary care
Background: In Germany, most patients with coronavirus disease 2019 (COVID-19) are treated in an outpatient setting. To improve assessments of the health status of COVID-19 outpatients, various remote monitoring models have been developed. However, little information exists on experiences acquired with remote monitoring in an outpatient setting, particularly from a patient perspective. The aim of our ‘COVID-19@home’ study was therefore to implement and evaluate an app-based remote monitoring concept for acute and post-acute COVID-19-patients in primary care. In this paper, we focus on the patients’ evaluation of our remote monitoring approach. Methods: Patients with acute COVID-19 measured heart rate, blood pressure, oxygen saturation, and body temperature daily for 28 days. Patients with post-acute COVID-19 determined the same parameters for 12 weeks, supplemented by lung parameters and daily step count. The data were documented using the ‘SaniQ’ smartphone app. COVID-19 symptoms were assessed daily using an app-based questionnaire. Patients’ GPs could access the data on the ‘SaniQ Praxis’ telemedicine platform. We used an app-based questionnaire consisting of 11 questions presented with a 4-point Likert scale to evaluate patient satisfaction. Data were analyzed descriptively. Results: Of the 51 patients aged 19-77 years that participated in the study, 42 completed the questionnaire. All patients rated home monitoring as ‘very good’ or ‘rather good’ and were able to integrate the measuring processes into their daily routines. Overall, 93% would recommend the app and the measuring devices to their family and friends. About 60% felt that their COVID-19 treatment had benefited from home monitoring. Only few patients were unsettled by the app and use of the measuring devices. During the course of the study, the implementation process was optimized. Conclusions: The use of remote monitoring in COVID-19 patients is feasible and was evaluated positively by most study patients. However, it is difficult to imagine how general practices could cope with monitoring patients with acute diseases without any further organizational support. Future research should address cost-effectiveness and changes in such clinical outcomes as hospitalization and mortality.
Open AccessImplementing remote monitoring for COVID-19 patients in primary care
Background: In Germany, most patients with coronavirus disease 2019 (COVID-19) are treated in an outpatient setting. To improve assessments of the health status of COVID-19 outpatients, various remote monitoring models have been developed. However, little information exists on experiences acquired with remote monitoring in an outpatient setting, particularly from a patient perspective. The aim of our ‘COVID-19@home’ study was therefore to implement and evaluate an app-based remote monitoring concept for acute and post-acute COVID-19-patients in primary care. In this paper, we focus on the patients’ evaluation of our remote monitoring approach. Methods: Patients with acute COVID-19 measured heart rate, blood pressure, oxygen saturation, and body temperature daily for 28 days. Patients with post-acute COVID-19 determined the same parameters for 12 weeks, supplemented by lung parameters and daily step count. The data were documented using the ‘SaniQ’ smartphone app. COVID-19 symptoms were assessed daily using an app-based questionnaire. Patients’ GPs could access the data on the ‘SaniQ Praxis’ telemedicine platform. We used an app-based questionnaire consisting of 11 questions presented with a 4-point Likert scale to evaluate patient satisfaction. Data were analyzed descriptively. Results: Of the 51 patients aged 19-77 years that participated in the study, 42 completed the questionnaire. All patients rated home monitoring as ‘very good’ or ‘rather good’ and were able to integrate the measuring processes into their daily routines. Overall, 93% would recommend the app and the measuring devices to their family and friends. About 60% felt that their COVID-19 treatment had benefited from home monitoring. Only few patients were unsettled by the app and use of the measuring devices. During the course of the study, the implementation process was optimized. Conclusions: The use of remote monitoring in COVID-19 patients is feasible and was evaluated positively by most study patients. However, it is difficult to imagine how general practices could cope with monitoring patients with acute diseases without any further organizational support. Future research should address cost-effectiveness and changes in such clinical outcomes as hospitalization and mortality.
- 17 January 2022
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 43, 67-77
A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
- 17 January 2022
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 43, 67-77
A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
- Open Access
Implementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: a scoping review protocol
Introduction mHealth refers to digital technologies that, via smartphones, mobile apps and specialised digital sensors, yield real-time assessments of patient’s health status. In the context of the COVID-19 pandemic, these technologies enable remote patient monitoring, with the benefit of timely recognition of disease progression to convalescence, deterioration or postacute sequelae. This should enable appropriate medical interventions and facilitate recovery. Various barriers, both at patient and technology levels, have been reported, hindering implementation and use of mHealth telemonitoring. As systematised and synthesised evidence in this area is lacking, we developed this protocol for a scoping review on mHealth home telemonitoring of acute COVID-19. Methods and analysis We compiled a search strategy following the PICO (Population, Intervention, Comparator, Outcome) and PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendation for Scoping Reviews) guidelines. MEDLINE, Embase and Web of Science will be searched from 1 March 2020 to 31 August 2021. Following the title and abstract screening, we will identify, systematise and synthesise the available knowledge. Based on pilot searches, we preview three themes for descriptive evidence synthesis. The first theme relates to implementation and use of mHealth telemonitoring, including reported barriers. The second theme covers the interactions of the telemonitoring team within and between different levels of the healthcare system. The third theme addresses how this telemonitoring warrants the continuity of care, also during disease transition into deterioration or postacute sequelae. Ethics and dissemination The studied evidence is in the public domain, therefore, no specific ethics approval is required. Evidence dissemination will be via peer-reviewed publications, conference presentations and reports to the policy makers.
Open AccessImplementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: a scoping review protocol
Introduction mHealth refers to digital technologies that, via smartphones, mobile apps and specialised digital sensors, yield real-time assessments of patient’s health status. In the context of the COVID-19 pandemic, these technologies enable remote patient monitoring, with the benefit of timely recognition of disease progression to convalescence, deterioration or postacute sequelae. This should enable appropriate medical interventions and facilitate recovery. Various barriers, both at patient and technology levels, have been reported, hindering implementation and use of mHealth telemonitoring. As systematised and synthesised evidence in this area is lacking, we developed this protocol for a scoping review on mHealth home telemonitoring of acute COVID-19. Methods and analysis We compiled a search strategy following the PICO (Population, Intervention, Comparator, Outcome) and PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendation for Scoping Reviews) guidelines. MEDLINE, Embase and Web of Science will be searched from 1 March 2020 to 31 August 2021. Following the title and abstract screening, we will identify, systematise and synthesise the available knowledge. Based on pilot searches, we preview three themes for descriptive evidence synthesis. The first theme relates to implementation and use of mHealth telemonitoring, including reported barriers. The second theme covers the interactions of the telemonitoring team within and between different levels of the healthcare system. The third theme addresses how this telemonitoring warrants the continuity of care, also during disease transition into deterioration or postacute sequelae. Ethics and dissemination The studied evidence is in the public domain, therefore, no specific ethics approval is required. Evidence dissemination will be via peer-reviewed publications, conference presentations and reports to the policy makers.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3693
Multidimensional scaling in Euclidean space of cytokine responses to document hyperinflammation in cystic fibrosis cells
Introduction: Studies of hyperinflammation in Cystic Fibrosis (CF) frequently yield complex high-dimensional data due to comparisons of CF cells with wildtype or treated controls, and multiple cytokine analyses. This warrants utilization of computational approaches beyond traditional statistics. We previously (Pediatr Pulmonol 2020;55/S2:56) utilized unsupervised clustering to assess a single-cytokine response in CF cells over two culture conditions. The Aim: of this study was to evaluate a composite cytokine response in CF cells under two culture conditions, in comparison with a known hyperinflammatory control. Methods: CFF16HBEge (delF508 CFTR) and 16HBE14o- (wildtype CFTR) were the cell models, tested either under submerged conditions or after differentiation at the air-liquid interface. The BEAS2B cells (wildtype CFTR) provided hyperinflammatory control data points, as per our previous work (Am J Respir Crit Care Med 2020;201:A2918). Basal and stimulated secretions of nine cytokines were quantified by multiplex ELISA (Millipore). The combined dataset, including the hyperinflammatory control, comprised 720 data points. All data points were log2 transformed and scaled to yield an Euclidean distance matrix for the multidimensional scaling (MDS) analysis. Results: The MDS analysis demonstrated proximity (i.e., similarity) of the composite inflammatory response of differentiated CFF16HBEge to that of the hyperinflammatory control. Conclusion: The developed workflow and MDS analysis support the presence of hyperinflammation in differentiated CF airway epithelial cells. Funding: Internal funds, DZL, Krieble Found., Gosselin Found., RSR-QC. ND, WA, ACH: co-first authors
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3693
Multidimensional scaling in Euclidean space of cytokine responses to document hyperinflammation in cystic fibrosis cells
Introduction: Studies of hyperinflammation in Cystic Fibrosis (CF) frequently yield complex high-dimensional data due to comparisons of CF cells with wildtype or treated controls, and multiple cytokine analyses. This warrants utilization of computational approaches beyond traditional statistics. We previously (Pediatr Pulmonol 2020;55/S2:56) utilized unsupervised clustering to assess a single-cytokine response in CF cells over two culture conditions. The Aim: of this study was to evaluate a composite cytokine response in CF cells under two culture conditions, in comparison with a known hyperinflammatory control. Methods: CFF16HBEge (delF508 CFTR) and 16HBE14o- (wildtype CFTR) were the cell models, tested either under submerged conditions or after differentiation at the air-liquid interface. The BEAS2B cells (wildtype CFTR) provided hyperinflammatory control data points, as per our previous work (Am J Respir Crit Care Med 2020;201:A2918). Basal and stimulated secretions of nine cytokines were quantified by multiplex ELISA (Millipore). The combined dataset, including the hyperinflammatory control, comprised 720 data points. All data points were log2 transformed and scaled to yield an Euclidean distance matrix for the multidimensional scaling (MDS) analysis. Results: The MDS analysis demonstrated proximity (i.e., similarity) of the composite inflammatory response of differentiated CFF16HBEge to that of the hyperinflammatory control. Conclusion: The developed workflow and MDS analysis support the presence of hyperinflammation in differentiated CF airway epithelial cells. Funding: Internal funds, DZL, Krieble Found., Gosselin Found., RSR-QC. ND, WA, ACH: co-first authors
- Open Access
- 1 June 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (6) , 1807-1808
Could relative abundance of airway lipoxins be the clue to restore corticosteroid sensitivity in severe asthma?
- 1 June 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (6) , 1807-1808
Open AccessCould relative abundance of airway lipoxins be the clue to restore corticosteroid sensitivity in severe asthma?
- Open Access
- 1 May 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (5) , 619-624
Reverse Transcription-Competitive Multiplex PCR Improves Quantification of mRNA in Clinical Samples—Application to the Low Abundance CFTR mRNA
Background: To monitor gene therapy, we wished to quantify cystic fibrosis transmembrane conductance regulator (CFTR) mRNA. We developed a PCR-based method to measure CFTR mRNA in clinical samples. Methods: Expression was determined by reverse transcription-competitive multiplex PCR (RCMP) for CFTR and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts, and for serial dilutions of two internal cDNA standards consisting of CFTR and GAPDH mutants containing short deletions. The RCMP used simultaneous amplification of the gene of interest with a reporter gene in one reaction tube. The expression of CFTR was calculated with reference to the amount of GAPDH to correct for variations in initial RNA loading. Results: Amplification of cDNAs derived from different amounts of RNA (1–4 μg) gave similar GAPDH/CFTR ratios, with a coefficient of variation (CV) below 7.5%. RCMP was applied on nasal and bronchial brushings and shows a high variability of CFTR expression in non-cystic fibrosis donors. Conclusion: This method is precise and reproducible and advantageous for use with limited amounts of tissue, such as from biopsies or from nasal or bronchial brushings.
- 1 May 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (5) , 619-624
Open AccessReverse Transcription-Competitive Multiplex PCR Improves Quantification of mRNA in Clinical Samples—Application to the Low Abundance CFTR mRNA
Background: To monitor gene therapy, we wished to quantify cystic fibrosis transmembrane conductance regulator (CFTR) mRNA. We developed a PCR-based method to measure CFTR mRNA in clinical samples. Methods: Expression was determined by reverse transcription-competitive multiplex PCR (RCMP) for CFTR and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts, and for serial dilutions of two internal cDNA standards consisting of CFTR and GAPDH mutants containing short deletions. The RCMP used simultaneous amplification of the gene of interest with a reporter gene in one reaction tube. The expression of CFTR was calculated with reference to the amount of GAPDH to correct for variations in initial RNA loading. Results: Amplification of cDNAs derived from different amounts of RNA (1–4 μg) gave similar GAPDH/CFTR ratios, with a coefficient of variation (CV) below 7.5%. RCMP was applied on nasal and bronchial brushings and shows a high variability of CFTR expression in non-cystic fibrosis donors. Conclusion: This method is precise and reproducible and advantageous for use with limited amounts of tissue, such as from biopsies or from nasal or bronchial brushings.